The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.

This study has been completed.

Study NCT00154362 Information provided by Novartis

First Received: September 8, 2005 Last Updated: November 29, 2007 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	December 2006
Estimated Primary Completion Date:	No date given